Netherlocks partial stroke system meets SIL 3

Published: 29-Apr-2010
Manufacturing

According to FMEDA report by Exida, the Netherlocks partial stoke system FAITH (Fail Action Integrity Test Handling) is very reliable

The FMEDA report showed the Netherlocks partial stoke system FAITH (Fail Action Integrity Test Handling) to be very reliable, with 0 Fail Safe Detected, Fail Safe Undetected and Fail Dangerous Detected conditions recorded from the tests. For most cases, the FAITH is suitable for use in SIL3 applications.

The FAITH system makes it possible to carry out a manually initiated partial stroke test on ESD (Emergency Shut Down) valves during normal operation, without interrupting process flow. It limits, with mechanical stops, the angle of the stroke of the valve-actuator combination to a set percentage – ensuring the ESD valve ‘works’, without actually shutting down the operation. By operating mechanically rather than relying on electronic contacts or signals, reliability and simplicity is maximised.

An FMEDA (Failure Modes, Effects, and Diagnostic Analysis) assessment has been carried out by Exida on Netherlocks’ FAITH system. The product was subject to a thorough examination according to IEC 61508 to determine Probability of Failure on Demand (PFD) statistics for this device. The failure rates of the FAITH System must be added to the failure rates of the valve-actuator combination when determining the PFD AVG and Safe Failure Fraction (SFF) for the final element.

More details, a summary and the report itself are available to customers upon request from sales@netherlocks.com or at www.netherlocks.com.
See more

You may also like

Manufacturing

Two leading valve operation brands merge to form Sofis

Read more
Netherlocks and Smith Flow Control reveal new corporate identity

Trending Articles

  1. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Rice-ing to the occasion: how plant-based excipients are gaining ground in pharmaceutical manufacturing As clean-label expectations migrate from health foods into pharmaceutical supply chains, natural ingredient supplier RIBUS says that rice-based excipients are becoming a credible alternative to synthetic standards
  3. Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
  4. Lonza delivers strong performance in Q1 2026 in line with expectations and confirms full-year Outlook 2026 Basel, Switzerland, 8 May 2026 – In its qualitative Q1 2026 business update, Lonza1 reported a strong performance across its CDMO business in line with the expected trajectory for Full-Year 2026. As expected, due to a lower prior year base, campaign timing and product releases, and planned site shutdowns, CER sales growth and CORE EBITDA margin will be notably stronger in the first half of 2026 than in the second half
  5. Piramal Pharma Solutions unveils state-of-the-art payload-linker suite at its Riverview, Michigan facility The Riverview facility provides comprehensive services for active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs), including specialised solutions for payload-linkers. This cutting-edge suite will significantly enhance the company’s ability to support global payload-linker development and manufacturing and help partners bring complex therapies like antibody-drug conjugates (ADCs) and other bioconjugates to market

Upcoming event

Cleanroom Technology Conference UK

20-21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Two leading valve operation brands merge to form Sofis

Netherlocks and Smith Flow Control reveal new corporate identity
Manufacturing

Replacing discontinued OEM degasser modules

Biotech Fluidics introduces direct replacement OEM degasser modules based on upgraded vacuum technology to support continued fluidic instrument supply without costly redesigns
Manufacturing

etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage

etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027
Manufacturing

CARBOGEN AMCIS introduces SPRINT for early-phase development

A new, phase-appropriate approach designed to accelerate early-phase progression while maintaining scientific rigour
Manufacturing

FUJIFILM Cellular Dynamics opens new iPSC manufacturing facility in US

The new site will serve as the company's headquarters and will increase Fujifilm's capacity for induced pluripotent stem cell development and manufacturing, as demand increases with new approach methods in research
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

From bespoke to scalable: closing the manufacturing gap in advanced therapeutics

Dr Kevin Robinson (KSR) spoke to Cytiva’s Nicolas Pivet (NP), Vice President of Manufacturing and Digital Solutions, to find out how digitalisation and scalable manufacturing platforms are shaping the next phase of advanced therapeutics
Manufacturing

Piramal Pharma Solutions announces partnership with Botanix to support drug substance development

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra. Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis. Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra
Subscribe now